Skip to main content

Acute Myeloid Leukemia

Featured Article
Gemtuzumab ozogamicin is safe and tolerable in patients with acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL), but combinations of the drug may be of more value to patients with…
Acute myeloid leukemia (AML) is characterized by an increase of malignant myeloid progenitor cells at the expense of mature blood cells.


AML is the most common acute leukemia in adults with an estimated 21,450 new cases expected in 2019 in the United States and approximately 10,920 deaths. In this segment, we explore various treatments for AML.
S Russell Spjut, PharmD, discusses current first-line therapies and new treatment opions used to treat acute myeloid leukemia and their associated costs. 
Back to Top